Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial

JAMA

Volumn 312, Issue 4, 2014, Pages 380-389

  Stanley, Takara L ^a   Feldpausch, Meghan N ^a   Oh, Jinhee ^a   Branch, Karen L ^a   Lee, Hang ^a   Torriani, Martin ^a   Grinspoon, Steven K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GLUCOSE; GROWTH HORMONE; INSULIN; PLACEBO; SOMATOMEDIN C; TESAMORELIN;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; AGED; ARTERIAL WALL THICKNESS; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BLOOD PRESSURE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GROWTH HORMONE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE STINGING; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID HOMEOSTASIS; LIPID TO WATER PERCENTAGE; LIVER FAT; MALE; MEDICATION COMPLIANCE; METABOLIC PARAMETERS; MYALGIA; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINUSITIS; SUBCUTANEOUS FAT;

ABDOMINAL FAT; ADIPOSITY; ADULT; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HIV INFECTIONS; HUMANS; INTRA-ABDOMINAL FAT; LIVER; MALE; MIDDLE AGED;

EID: 84904543851     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.8334     Document Type: Article

References (34)

1. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to ametabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250-257. (Pubitemid 351920629)
2. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr. 2007;46(3):312-317. (Pubitemid 350287358)
3. Perseghin G. Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. Diabetes Care. 2011;34(suppl 2):S367-S370.
4. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464-473.
5. Glesby MJ, Albu J, Chiu YL, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013;8(4):e61160.
6. He Q, Engelson ES, Kotler DP, Albu JB, Chiu YL, Glesby MJ. Effect of recombinant human growth hormone (rhGH) and rosiglitazone (rosi) on liver fat in people with HIV-associated abdominal obesity and insulin resistance. Abstract presented at: 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV;Washington, DC; July 19-21, 2012. Abstract P10.
7. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (Pubitemid 350223390)
8. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
9. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64(5):685-693. (Pubitemid 26398268)
10. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2):210-218. (Pubitemid 38917998)
11. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. (Pubitemid 41224897)
12. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982;36(1):172-177. (Pubitemid 12000247)
13. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300(5):509-519.
14. Bredella MA, Ghomi RH, Thomas BJ, et al. Breath-hold 1H-magnetic resonance spectroscopy for intrahepatic lipid quantification at 3 tesla. J Comput Assist Tomogr. 2010;34(3):372-376.
15. 1H MR spectroscopy. Radiology. 2005;236(2):609-614.
16. Chan R, Kaufhold J, Hemphill LC, Lees RS, Karl WC. Anisotropic edge-preserving smoothing in carotid B-mod ultrasound for improved segmentation and intima-media thickness (IMT) measurement. Comput Cardiol. 2000;27:37-40. (Pubitemid 32188201)
17. Georgoff P, Thomasson D, Louie A, et al. Hydrogen-1MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol. 2012;199(1):2-7.
18. Thaete FL, Colberg SR, Burke T, Kelley DE. Reproducibility of computed tomography measurement of visceral adipose tissue area. Int J Obes Relat Metab Disord. 1995;19(7):464-467.
19. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care. 1990;13(4):401-411. (Pubitemid 20109476)
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. (Pubitemid 15018832)
21. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2002;87(2):942.
22. Goodman HM. Effects of chronic growth hormone treatment on lipogenesis by rat adipose tissue. Endocrinology. 1963;72:95-99.
23. Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167(1):67-74.
24. Gardner CJ, Irwin AJ, Daousi C, et al. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol. 2012;166(6):993-1002.
25. Crum-Cianflone N, Krause D, Wessman D, et al. Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons. HIV Med. 2011;12(8):463-471.
26. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887. (Pubitemid 46024995)
27. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404.
28. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-1350.
29. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011;96(11):1756-1760.
30. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond). 2010;34(6):949-959.
31. Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117(9):2621-2637. (Pubitemid 47494363)
32. Nielsen S, Møller N, Christiansen JS, Jørgensen JO. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes. 2001;50(10):2301-2308. (Pubitemid 33641915)
33. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.
34. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22 (14):1719-1728.